Kyowa Kirin
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.50 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 9 disclosed transactions, Kyowa Kirin concentrates its licensing activity in Oncology, Hematology, and Other. Kyowa Kirin pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.50x). Their most common deal structure is License, with an average disclosed value of $1.0B. Most recent activity: 2024.
Premium by therapeutic area
How Kyowa Kirin pays relative to peer medians in each TA
Pipeline coverage & gaps
Kyowa Kirin has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $177M | $919M |
| Co Development | 1 | $330M | $1.5B |
| Acquisition | 1 | $330M | $1.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Ziftomenib | Kura Oncology, Inc. | KMT2A-rearranged acute myeloid leukemia (AML) | phase_1 | $330M | $1.5B |
| 2024 | ziftomenib (KO-539) | Kura Oncology | acute myeloid leukemia (AML) | phase_2 | $330M | $1.5B |
| 2024 | Ziftomenib (KO-539) | Kura Oncology | acute myeloid leukemia (relapsed/refractory) and acute leukemias | phase_3 | $330M | $1.8B |
| 2024 | Ziftomenib | Kura Oncology | Acute myeloid leukemia (AML) | phase_2 | $330M | $1.5B |
| 2024 | Ziftomenib | Kura Oncology | Acute myeloid leukemia (AML) and hematologic malignancies | phase_2 | $330M | $1.2B |
| 2024 | infigratinib | BridgeBio Pharma | achondroplasia, hypochondroplasia, skeletal dysplasias | phase_3 | $100M | $181M |
| 2020 | ME-401 (zandelisib) | MEI Pharma | follicular lymphoma | phase_2 | $100M | $683M |
| 2019 | tivozanib | AVEO Pharmaceuticals | non-oncology indications | approved | $25M | $416M |
| 2019 | tivozanib | AVEO Oncology | non-oncology indications | unknown | $25M | $416M |
How this is computed
For each Kyowa Kirin deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.582, clamped to [0.7, 1.5].